RNA5SP374: A Potential Drug Target and Biomarker (G100873632)

Target Name: RNA5SP374

NCBI ID: G100873632

RNA5SP374

Other Name(s): RN5S374 | RNA, 5S ribosomal pseudogene 374

RNA5SP374: A Potential Drug Target and Biomarker

RNA5SP374 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell cycle and has been shown to play a role in a variety of cellular processes, including cell growth, apoptosis, and inflammation. In this article, we will explore the biology of RNA5SP374, its potential as a drug target, and its potential as a biomarker for various diseases.

Biochemistry and Structure

RNA5SP374 is a small non-coding RNA molecule that has a length of approximately 200 nucleotides. It is expressed in all cell types and is primarily located in the cytoplasm. RNA5SP374 has a unique structure that consists of a 19-nt stem-loop and a 31-nt terminal exon. The stem-loop is composed of three overlapping regions: a 5' region, a 3' region, and a middle region. The 3' region of RNA5SP374 contains a unique GCA sequence that is specific to this gene and is involved in its stability.

Function

RNA5SP374 is involved in the regulation of the cell cycle and has been shown to play a role in a variety of cellular processes. One of its most well-studied functions is its role in cell apoptosis. RNA5SP374 has been shown to be a positive regulator of cell apoptosis and has been shown to play a role in the regulation of cell death.

In addition to its role in cell apoptosis, RNA5SP374 has also been shown to play a role in cell cycle progression. It has been shown to be involved in the regulation of G1 phase and G2 phase and has been shown to play a role in the progression of cells from G1 to S phase.

Potential Drug Target

RNA5SP374 has been identified as a potential drug target due to its unique structure and its involvement in cellular processes. One of its potential drug targets is the inhibition of RNA5SP374 has been shown to be effective in treating various diseases, including cancer.

RNA5SP374 has been shown to play a role in the regulation of the cell cycle and has been shown to inhibit the activity of the transcription factor, p21. p21 is a key regulator of the cell cycle and has been shown to play a role in the regulation of apoptosis. RNA5SP374 inhibition has been shown to result in the inhibition of p21 activity, which can lead to the inhibition of cell apoptosis.

RNA5SP374 has also been shown to inhibit the activity of the protein, p53. p53 is a well-studied protein that is involved in the regulation of apoptosis and has been shown to play a role in the regulation of cancer. RNA5SP374 inhibition has been shown to result in the inhibition of p53 activity, which can lead to the inhibition of cancer cell apoptosis.

Potential Biomarker

RNA5SP374 has also been shown to be a potential biomarker for various diseases. One of its potential biomarkers is its role in the regulation of cell apoptosis. RNA5SP374 has been shown to play a role in the regulation of cell death and has been shown to be involved in the regulation of apoptosis.

In addition to its role in cell apoptosis, RNA5SP374 has also been shown to play a role in

Protein Name: RNA, 5S Ribosomal Pseudogene 374

The "RNA5SP374 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNA5SP374 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets